Silver Lake Advisory LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 7.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 32,820 shares of the company’s stock after selling 2,567 shares during the quarter. Johnson & Johnson makes up 3.0% of Silver Lake Advisory LLC’s investment portfolio, making the stock its 5th largest holding. Silver Lake Advisory LLC’s holdings in Johnson & Johnson were worth $4,615,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the stock. Sector Gamma AS boosted its position in Johnson & Johnson by 0.3% in the 1st quarter. Sector Gamma AS now owns 117,532 shares of the company’s stock valued at $15,412,000 after buying an additional 303 shares during the period. Tradewinds Capital Management LLC grew its position in shares of Johnson & Johnson by 1.3% during the first quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock worth $997,000 after buying an additional 101 shares in the last quarter. Pennsylvania Trust Co increased its stake in shares of Johnson & Johnson by 1.3% during the first quarter. Pennsylvania Trust Co now owns 409,496 shares of the company’s stock worth $53,698,000 after buying an additional 5,413 shares during the period. Private Asset Management Inc. raised its holdings in Johnson & Johnson by 0.5% in the second quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock valued at $13,213,000 after acquiring an additional 425 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board lifted its stake in Johnson & Johnson by 5.2% in the first quarter. Ontario Teachers Pension Plan Board now owns 555,611 shares of the company’s stock worth $72,857,000 after acquiring an additional 27,525 shares during the last quarter. Hedge funds and other institutional investors own 68.44% of the company’s stock.
Several equities research analysts have recently issued reports on JNJ shares. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a research report on Tuesday, July 7th. Morgan Stanley upped their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Citigroup raised their target price on Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price target on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $163.38.
Shares of Johnson & Johnson stock opened at $145.76 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.05 and a current ratio of 1.25. The company has a market capitalization of $383.76 billion, a P/E ratio of 21.31, a PEG ratio of 3.23 and a beta of 0.69. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The company’s fifty day moving average is $144.04 and its two-hundred day moving average is $144.14.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.